-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 23, Hainan Puli Pharmaceuticals issued an announcement stating that the company recently received an End of Procedure from the European Commission for the Evaluation of Drugs (CBG), which means that the company’s desloratadine dry suspension The drug has successfully passed the review by the Dutch Drug Evaluation Board (CBG) and the German Federal Agency for Drugs and Medical Devices (BfArM), and will soon be approved for marketing in the Netherlands and Germany
.
Deloratadine is a non-sedative, long-acting tricyclic antihistamine, and is the active metabolite of loratadine.
It can selectively block peripheral H1 receptors and inhibit various allergic inflammations.
The release of chemical media can be used to relieve allergic rhinitis and urticaria related symptoms in adults, adolescents 12 years and older, and children 6-11 years old
.
Desloratadine was developed by Sepracor, Schering-Plough, and listed in 53 countries around the world
.
The 2.